TheBrief.Health
Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.
518 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af TheBrief.Health-fællesskabet!